Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03818776 · ClinicalTrials.gov registry record · Early Phase 1
Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC
A Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT03818776 is a Early Phase 1 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 7 participants.
The verdict
NCT03818776, a Early Phase 1 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to treat participants with the combination of durvalumab (the study drug) and proton beam therapy. Proton beam therapy is a type of radiotherapy (RT) with a unique characteristic where the proton stops at a specific depth according to its energy. This may be advantageous in treating lung cancer because it allows for a sufficient tumor dose that may improve local control and survival while sparing normal organs at risk, such as the heart, lung, and spinal cord.
Interventions
- DRUG Durvalumab
- RADIATION Proton beam therapy RT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-08-30 |
| Est. Completion | 2022-01-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03818776
The ClinicalTrials.gov registry entry for NCT03818776 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT03818776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03818776 about?
NCT03818776 is a clinical study titled "Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC". The purpose of this study is to treat participants with the combination of durvalumab (the study drug) and proton beam therapy. Proton beam therapy is a type of radiotherapy (RT) with a unique characteristic where the proton stops at a specific depth according to its energy. This may be advantageous...
What is the current status of trial NCT03818776?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2019-08-30. Estimated completion is 2022-01-27.
What interventions are being tested in trial NCT03818776?
The interventions under investigation include: Durvalumab (DRUG), Proton beam therapy RT (RADIATION).
Who is sponsoring clinical trial NCT03818776?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.